Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

On Tuesday, Organon & Co (OGN) stock saw a decline, ending the day at $16.46 which represents a decrease of $-0.46 or -2.72% from the prior close of $16.92. The stock opened at $16.74 and touched a ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Despite announcing strong earnings, Organon & Co.'s ( NYSE:OGN ) stock was sluggish. We did some digging and found ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), reducing the price target to $17.00.

Organon Philippines, a women’s health company, recently unveiled its Her Health Finder, an online tool that aims to empower ...

On October 30, 2024, Shanghai Henlius Biotech and Organon announced that the FDA has accepted the Biologic License Application (BLA) for HLX14, a proposed biosimilar to PROLIA/XGEVA (denosumab). In ...

Q3 2024 Earnings Call Transcript October 31, 2024 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...

Organon & Co. ( (OGN)) has released its Q3 earnings. Here is a breakdown of the information Organon & Co. presented to its investors. Organon & Co. is a global healthcare company focused on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Henlius and Organon announced US FDA has accepted the Biologics License Application (BLA) for HLX14, biosimilar candidate of ...

Organon said the Food and Drug Administration extended by three months its review of an application seeking expanded approval of the healthcare company's recently acquired skin-care cream Vtama.